51 related articles for article (PubMed ID: 16178771)
1. Anthracyclines React with Apurinic/Apyrimidinic Sites in DNA.
Bellamri M; Terrell JT; Brandt K; Gruppi F; Turesky RJ; Rizzo CJ
ACS Chem Biol; 2023 Jun; 18(6):1315-1323. PubMed ID: 37200590
[TBL] [Abstract][Full Text] [Related]
2. Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts.
Parker BS; Cutts SM; Cullinane C; Phillips DR
Nucleic Acids Res; 2000 Feb; 28(4):982-90. PubMed ID: 10648792
[TBL] [Abstract][Full Text] [Related]
3.
Emms VL; Lewis LA; Beja L; Bulman NFA; Pires E; Muskett FW; McCullagh JSO; Swift LP; McHugh PJ; Hopkinson RJ
Chem Sci; 2023 Nov; 14(44):12498-12505. PubMed ID: 38020377
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Effect of Endogenous and Exogenous Aldehydes on Doxorubicin Toxicity in Yeast.
Miles JS; Sojourner SJ; Whitmore AM; Freeny D; Darling-Reed S; Flores-Rozas H
Biomed Res Int; 2018; 2018():4938189. PubMed ID: 30003101
[TBL] [Abstract][Full Text] [Related]
5. DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.
Stornetta A; Zimmermann M; Cimino GD; Henderson PT; Sturla SJ
Chem Res Toxicol; 2017 Jan; 30(1):388-409. PubMed ID: 27936622
[TBL] [Abstract][Full Text] [Related]
6. Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations.
Coldwell KE; Cutts SM; Ognibene TJ; Henderson PT; Phillips DR
Nucleic Acids Res; 2008 Sep; 36(16):e100. PubMed ID: 18632763
[TBL] [Abstract][Full Text] [Related]
7. Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.
Cutts SM; Rephaeli A; Nudelman A; Ugarenko M; Phillips DR
Curr Top Med Chem; 2015; 15(14):1409-22. PubMed ID: 25866273
[TBL] [Abstract][Full Text] [Related]
8. Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate.
Cutts SM; Swift LP; Pillay V; Forrest RA; Nudelman A; Rephaeli A; Phillips DR
Mol Cancer Ther; 2007 Apr; 6(4):1450-9. PubMed ID: 17431124
[TBL] [Abstract][Full Text] [Related]
9. Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways.
Bilardi RA; Kimura KI; Phillips DR; Cutts SM
Biochem Pharmacol; 2012 May; 83(9):1241-50. PubMed ID: 22326903
[TBL] [Abstract][Full Text] [Related]
10. The power and potential of doxorubicin-DNA adducts.
Cutts SM; Nudelman A; Rephaeli A; Phillips DR
IUBMB Life; 2005 Feb; 57(2):73-81. PubMed ID: 16036566
[TBL] [Abstract][Full Text] [Related]
11. The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts.
Forrest RA; Swift LP; Evison BJ; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Chemother Pharmacol; 2013 Mar; 71(3):809-16. PubMed ID: 23263186
[TBL] [Abstract][Full Text] [Related]
12. Structural requirements for the formation of anthracycline-DNA adducts.
Cutts SM; Parker BS; Swift LP; Kimura KI; Phillips DR
Anticancer Drug Des; 2000 Oct; 15(5):373-86. PubMed ID: 11354313
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde.
Cutts SM; Swift LP; Rephaeli A; Nudelman A; Phillips DR
Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):431-47. PubMed ID: 16178771
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
